Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – Lung cancer patients undergoing chemotherapy can be treated safely with erythropoiesis-stimulating agents (ESAs), according to findings published in the 24 January online issue…
NEW YORK (Reuters Health) – Men 60 years old and younger have excellent quality-of-life outcomes after proton therapy for prostate cancer, according to findings published in the January…
NEW YORK (Reuters Health) – Stereotactic body radiotherapy (SBRT) may be an effective alternative to surgery for solitary pulmonary nodules clinically diagnosed as lung cancer, researchers from Japan…
NEW YORK (Reuters Health) – Adding the multitargeted tyrosine kinase inhibitor sunitinib (Sutent; Pfizer) to docetaxel did not improve clinical outcomes when used in the first-line setting in…
NEW YORK (Reuters Health) – Some elderly patients with unresected non-small cell lung cancer (NSCLC) may do better with chemoradiotherapy (CRT) than with radiotherapy (RT) alone. However, low…
NEW YORK (Reuters Health) – While treatment of several malignancies with VEGFR (vascular endothelial growth factor receptor) tyrosine kinase inhibitors has improved patient outcomes, the agents are associated…
NEW YORK (Reuters Health) – The risk of cancer recurrence is increased slightly after laparoscopic rather than open surgical management of uterine cancer, according to study findings reported…
NEW YORK (Reuters Health) – The risk of cancer recurrence is increased slightly after laparoscopic rather than open surgical management of uterine cancer, according to study findings reported…
NEW YORK (Reuters Health) – About one in four patients with peripheral T-cell lymphoma (PTCL) who do not respond to or relapse after systemic therapy are likely to…
NEW YORK (Reuters Health) – Women with early-stage estrogen receptor-positive breast cancer fare somewhat better with 2 years of tamoxifen followed by 3 years of anastrozole than with…
